

Title (en)  
IMMUNOTHERAPEUTIC COMBINATION FOR TREATING CANCER

Title (de)  
IMMUNOTHERAPEUTISCHE KOMBINATION ZUR BEHANDLUNG VON KREBS

Title (fr)  
ASSOCIATION D'IMMUNOTHÉRAPIES POUR LE TRAITEMENT DU CANCER

Publication  
**EP 3930747 A4 20230405 (EN)**

Application  
**EP 20763489 A 20200227**

Priority

- US 201962811459 P 20190227
- US 201962825487 P 20190328
- US 201962838180 P 20190424
- US 201962881832 P 20190801
- US 2020020224 W 20200227

Abstract (en)  
[origin: WO2020176797A1] Provided herein are methods, combinations, and compositions for treating a subject having cancer by administering to the subject an individualized neoantigen DNA cancer vaccine in combination with a T cell expanding compound ("T cell expander"), i.e., a compound capable of driving specific clonal T cell expansion to vaccine epitopes, optionally further combined with a checkpoint inhibitor.

IPC 8 full level  
**A61K 39/00** (2006.01); **A61P 35/00** (2006.01); **C07K 16/28** (2006.01); **C12N 7/00** (2006.01)

CPC (source: EP)  
**A61K 39/0011** (2013.01); **A61K 39/00119** (2018.08); **A61K 39/39** (2013.01); **A61K 39/3955** (2013.01); **A61P 35/00** (2018.01); **C07K 16/2818** (2013.01); **A01K 2207/12** (2013.01); **A01K 2227/105** (2013.01); **A01K 2267/0331** (2013.01); **A61K 2039/505** (2013.01); **A61K 2039/53** (2013.01); **A61K 2039/55533** (2013.01); **A61K 2039/55561** (2013.01); **A61K 2039/572** (2013.01); **A61K 2039/70** (2013.01); **A61K 2039/82** (2018.08); **A61K 2039/876** (2018.08)

C-Set (source: EP)  
1. **A61K 39/00119 + A61K 2300/00**  
2. **A61K 39/0011 + A61K 2300/00**  
3. **A61K 39/3955 + A61K 2300/00**

Citation (search report)

- [XYI] WO 2018089669 A2 20180517 - NEKTAR THERAPEUTICS [US]
- [Y] US 2017216403 A1 20170803 - WITTRUP KARL DANE [US], et al
- [Y] XUE WEI ET AL: "SCIB1, a hulgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors", ONCOTARGET, vol. 7, no. 50, 13 December 2016 (2016-12-13), pages 83088 - 83100, XP093025668, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347755/pdf/oncotarget-07-83088.pdf> DOI: 10.18632/oncotarget.13070
- [A] ELIZABETH I. BUCHBINDER ET AL: "CTLA-4 and PD-1 Pathways : Similarities, Differences, and Implications of Their Inhibition", AMERICAN JOURNAL OF CLINICAL ONCOLOGY (CANCER CLINICAL TRIALS)., vol. 39, no. 1, 1 February 2016 (2016-02-01), US, pages 98 - 106, XP055393184, ISSN: 0277-3732, DOI: 10.1097/COC.0000000000000239
- See also references of WO 2020176797A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**WO 2020176797 A1 20200903**; CN 113631185 A 20211109; EP 3930747 A1 20220105; EP 3930747 A4 20230405; JP 2022521792 A 20220412

DOCDB simple family (application)  
**US 2020020224 W 20200227**; CN 202080025990 A 20200227; EP 20763489 A 20200227; JP 2021550014 A 20200227